SUMMIT, N.J.--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced today that it’s oral cancer drug, REVLIMID (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. This approval represents the first regulatory approval for Celgene in Switzerland, and REVLIMID represents the first oral therapy in Switzerland for multiple myeloma patients in more than forty years. REVLIMID is currently approved by the U.S. Food and Drug Administration (FDA) under 21 CFR 314.500, Acclerated Approval of New Drugs for Serious or Life-Threatening Illnesses.
